|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-8.96/-7.20
|
企業價值
93.79M
|
資產負債 |
每股賬面淨值
1.61
|
現金流量 |
現金流量率
--
|
損益表 |
收益
7.88M
|
每股收益
1.73
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/15 01:19 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advancedsolid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |